Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Sol
Go back to Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Sol| (NASDAQ: ALLO) | Delayed: 2.05 +0.07 (3.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.98 | 52 Week High | $ | |||
| Open | $1.96 | 52 Week Low | $ | |||
| Day High | $2.08 | P/E | N/A | |||
| Day Low | $1.92 | EPS | $ | |||
| Volume | 4,605,159 | |||||
